RBC Capital started coverage on shares of Dyax Corp. (NASDAQ:DYAX) in a research report released on Tuesday morning, TheFlyOnTheWall.com reports. The firm issued an outperform rating and a $15.00 price objective on the stock. Dyax Corp. (NASDAQ:DYAX) shares after opening at $9.05 moved to $9.20 on last trade day and at the end of the day closed at $8.28. Company price to sales ratio in past twelve months was calculated as 18.37 and price to cash ratio as 8.89. Dyax Corp. (NASDAQ:DYAX) showed a negative weekly performance of -9.80%.
Securities lawyers at Deans & Lyons announce an investigation of the board of Galena Biopharma, Inc. (NASDAQ:GALE). Concerned GALE investors who purchased between November 6, 2013 and February 14, 2014 are encouraged to contact securities attorney Hamilton Lindley. Galena Biopharma Inc. (NASDAQ:GALE) shares fell -7.72% in last trading session and ended the day on $2.39. GALE return on equity ratio is recorded as -435.40% and its return on assets is -113.60%. Galena Biopharma Inc. (NASDAQ:GALE) yearly performance is 14.90%.
XOMA Corp (NASDAQ:XOMA) CEO John Varian unloaded 21,329 shares of the company’s stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $6.32, for a total value of $134,799.28. Following the sale, the chief executive officer now directly owns 285,613 shares of the company’s stock, valued at approximately $1,805,074. XOMA Corp (NASDAQ:XOMA) shares moved down -6.85% in last trading session and was closed at $5.03, while trading in range of $5.00 – $5.53. XOMA Corp (NASDAQ:XOMA) year to date (YTD) performance is -25.26%.
Synthetic Biologics, Inc. (NYSEMKT:SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and other diseases, announced that it intends to release its financial results for the year ended December 31, 2013 on Monday, March 31, 2014. Synthetic Biologics Inc. (NYSEMKT:SYN) weekly performance is -21.16%. On last trading day company shares ended up $2.72. Synthetic Biologics Inc. (NYSEMKT:SYN) distance from 50-day simple moving average (SMA50) is 12.16%. Analysts mean target price for the company is $3.94.
Leave a Reply